| Zacks Company Profile for OPKO Health, Inc. (OPK : NSDQ) |
|
|
| |
| • Company Description |
| OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.
Number of Employees: 2,997 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.36 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,209,227 shares |
| Shares Outstanding: 793.05 (millions) |
| Market Capitalization: $1,078.55 (millions) |
| Beta: 1.34 |
| 52 Week High: $2.04 |
| 52 Week Low: $1.21 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
1.49% |
-2.31% |
| 12 Week |
-4.23% |
-19.44% |
| Year To Date |
-7.48% |
-13.36% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Phillip Frost - Chief Executive Officer and Chairman of the Board
Elias A. Zerhouni - President and Vice Chairman
Adam Logal - Chief Financial Officer;Senior Vice President;Chie
Steven D. Rubin - Executive Vice President -Administration and Direc
Richard Krasno - Director
|
|
Peer Information
OPKO Health, Inc. (ABMD)
OPKO Health, Inc. (DMDS)
OPKO Health, Inc. (CPWY.)
OPKO Health, Inc. (EQUR)
OPKO Health, Inc. (ECIA)
OPKO Health, Inc. (FMS)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 68375N103
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 793.05
Most Recent Split Date: (:1)
Beta: 1.34
Market Capitalization: $1,078.55 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.07 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.33 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/06/25 |
|
|
|
| |
